問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

Chung Shan Medical University Hospital (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

蔡明宏Tsai, Ming-Hung
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

68Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡明宏

List

109Cases

2018-06-26 - 2030-12-31

Phase II

Active
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion

  • Condition/Disease

    Chronic Lymphocytic Leukemia

  • Test Drug

    Venetoclax

Participate Sites
8Sites

Recruiting7Sites

2020-07-01 - 2027-07-31

Phase I

Active
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Locally Advanced or Metastatic Solid Tumors

  • Test Drug

    ABBV-151

Participate Sites
6Sites

Recruiting6Sites

2019-10-23 - 2025-12-31

Phase I

Active
A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination with Ruxolitinib in Myeloproliferative Neoplasm Subjects

  • Condition/Disease

    Myelofibrosis (MF)

  • Test Drug

    Navitoclax

Participate Sites
2Sites

Recruiting2Sites

2019-01-08 - 2020-09-30

Phase I

Completed
A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

  • Condition/Disease

    Relapsed and/or Refractory Solid Tumors

  • Test Drug

    ABBV-155

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2020-04-20 - 2024-11-01

Phase I

Completed
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Locally Advanced or Metastatic Solid Tumors

  • Test Drug

    ABBV-927 、ABBV-368、Budigalimab (ABBV-181)

Participate Sites
2Sites

Recruiting2Sites

2018-11-15 - 2025-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-12-31 - 2025-10-01

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-12-01 - 2022-12-31

Phase II

Completed
A Study of Nivolumab Combination Gemcitabine and S1 as the First-Line Treatment in Patients With Advanced Biliary Tract Cancer

  • Condition/Disease

    Advanced Biliary Tract Cancer

  • Test Drug

    OPDIVO

Participate Sites
7Sites

Recruiting7Sites

2017-07-18 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-09-01 - 2026-10-02

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB